Our cholesterol franchise continues to be a critical growth driver.
We have now registered our fourth consecutive quarter of strong sales growth and our third consecutive quarter of higher earnings, excluding special items,
We continue to deliver on the promise we made when we began our turnaround in 1997 of achieving annual double digit earnings growth, ... Our results this quarter were again driven by strong growth in the U.S., where prescription sales increased 28 percent.
These changes allow us to focus even more effectively on the needs of our customers in different markets, to better manage and drive growth and to build a competitive edge through innovation, speed and flexibility.
We have delivered on our promise of achieving a turnaround in 1998 and double-digit earnings growth for the full year,